Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

BEAM-201 for the Treatment of Relapsed and/or Refractory (R/R) T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LL): Initial Data from the Phase (Ph) 1/2 Dose-Exploration, Dose-Expansion, Safety, and Efficacy Study of Multiplex Base-Edited Allogeneic Anti-CD7 CAR-T-Cells

Caroline Diorio, Paul Shaughnessy, Nosha Farhadfar, Anjali S. Advani, Wen-Kai Weng, Hagop Youssoufian, Guo Chen, Felicia Nguyen Brown, Bahru Habtermariam, Lalit Kumar, Jigar Patel, Shangbin (Gary) Liu, Sunita Goyal, Amy Simon, Alex C. Minella, David T. Teachey

Blood (2024) 144 (Supplement 1): 4838.

https://doi.org/10.1182/blood-2024-203546

Published: 2024

Journal Articles

Study of PC-002 (Sepantronium Bromide), a First-in-Class Inhibitor of Deubiquitinases (DUBs) Targeting Myc Degradation in Relapsed/Refractory c-Myc Rearranged High-Grade B Cell Lymphoma (HGBCL): Updated Phase 2 Results

Blood (2024) 144 (Supplement 1): 3120.

https://doi.org/10.1182/blood-2024-206700

Published: 2024

Journal Articles

Treatment of Relapsed/Refractory Hgbcl and Bukitt's Lymphoma with c-Myc Rearrangement: A Multi-Center, Open-Label, Phase 2 Study of PC-002 (SepB), a First-in-Class Deubiquitinase Inhibitor Inducing Myc Degradation

Blood (2023) 142 (Supplement 1): 1754.

https://doi.org/10.1182/blood-2023-190995

Published: 2023

Journal Articles

Duvelisib in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma from the Phase 2 Primo Trial: Dose Optimization Efficacy Update and Expansion Phase Initial Results

Barbara Pro, MD, Jonathan E. Brammer, MD, Carla Casulo, MD, Eric Jacobsen, MD, Monica Mead, MD BS, Neha Mehta-Shah, MD, Jasmine M. Zain, MD, Pier Luigi Zinzani, MD, Stephanie Lustgarten, PhD, Hagop Youssoufian, MD, Steven M. Horwitz, MD

Blood (2020) 136 (Supplement 1): 38–39.

https://doi.org/10.1182/blood-2020-140412

Published: 2020

Journal Articles

Dose Optimization of Duvelisib in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma from the Phase 2 Primo Trial: Selection of Regimen for the Dose-Expansion Phase

Steven M. Horwitz, MD, Neha Mehta-Shah, MD, Barbara Pro, MD, Eric D Jacobsen, MD, Carla Casulo, Jonathan E. Brammer, MD, Jeff Haney, Hagop Youssoufian, MD, David T. Weaver, PhD, Michael Baglio, PharmD, Jasminder Soto, Narayana Narasimhan, Jasmine Zain, MD

Blood (2019) 134 (Supplement_1): 1567.

https://doi.org/10.1182/blood-2019-121401

Published: 2019

Journal Articles

A Phase 2, Randomized, Open-Label, 2-Arm Study Comparing 2 Intermittent Dosing Schedules of Duvelisib in Patients with Indolent Non-Hodgkin Lymphoma (iNHL) (TEMPO)

Reem Karmali, MD, Hagop Youssoufian, MD, Kam Sprott, PhD, David T. Weaver, PhD, Narayana Narasimhan, Stephanie Lustgarten, PhD, Gloria Patrick, Alena Zalutskaya, Leo I. Gordon, MD

Blood (2019) 134 (Supplement_1): 5251.

https://doi.org/10.1182/blood-2019-124406

Published: 2019

Journal Articles

Phase 1b Study of the Epichaperome Inhibitor PU-H71 Administered Orally with Ruxolitinib Continuation for the Treatment of Patients with Myelofibrosis

Naveen Pemmaraju, MD, Krishna Gundabolu, MBBS, Kristen Pettit, MD, Moshe Talpaz, MD, Nikolai A. Podoltsev, MD PhD, Gary J. Schiller, MD, Peter Eisenberg, MD, Hagop Youssoufian, MD, Susan Duggan, RN, MBA, Barbara Wallner, PhD, Srdan Verstovsek, MD PhD

Blood (2019) 134 (Supplement_1): 4178.

https://doi.org/10.1182/blood-2019-130310

Published: 2019

Journal Articles

Phase 1 MMRC Trial of Selinexor, Carfilzomib (CFZ), and Dexamethasone (DEX) in Relapsed and Relapsed/Refractory Multiple Myeloma (RRMM)

Andrzej Jakubowiak, MD PhD, Jagoda Jasielec, MD, Cara A. Rosenbaum, MD, Jeffrey A Zonder, MD, Craig E. Cole, MD, Ajai Chari, MD, Jennifer Nam, Leonor A Stephens, PhD, Kathryn McDonnell, Rebecca Uribe, Shaun Rosebeck, PhD, Tami Rashal, MD, Hagop Youssoufian, MD, Sarah Henry, Sharon Shacham, Michael Kauffman, MD PhD, Todd Zimmerman, MD, Theodore Karrison, PhD

Blood (2015) 126 (23): 4223.

https://doi.org/10.1182/blood.V126.23.4223.4223

Published: 2015

Journal Articles

Phase I Study of Selinexor, a Selective Inhibitor of Nuclear Export, in Combination with Fludarabine and Cytarabine in Pediatric Patients with Relapsed or Refractory AML

Jeffrey E Rubnitz, MD PhD, Ronda Kaufman, PhD, Raul C. Ribeiro, MD, Boris Klebanov, MA, MS, Joel Ellis, PhD, Yosef Landesman, PhD, Hagop Youssoufian, MD, Tami Rashal, MD, Sharon Shacham

Blood (2015) 126 (23): 1345.

https://doi.org/10.1182/blood.V126.23.1345.1345

Published: 2015

Journal Articles

Correction of cross-linker sensitivity of Fanconi anemia group F cells by CD33-mediated protein transfer

Rebecca K. Holmes, Karine Harutyunyan, Maulik Shah, Hans Joenje, Hagop Youssoufian

Blood (2001) 98 (13): 3817–3822.

https://doi.org/10.1182/blood.V98.13.3817

Published: 2001

Journal Articles

Targeting of a Heterologous Protein to a Regulated Secretion Pathway in Cultured Endothelial Cells

Yvonne H. Datta, Hagop Youssoufian, Peter W. Marks, Bruce M. Ewenstein

Blood (1999) 94 (8): 2696–2703.

https://doi.org/10.1182/blood.V94.8.2696.420k29_2696_2703

Published: 1999

Journal Articles

Expression of the Fanconi Anemia Group A Gene ( Fanca ) During Mouse Embryogenesis

Radwan Abu-Issa, Gregor Eichele, Hagop Youssoufian

Blood (1999) 94 (2): 818–824.

https://doi.org/10.1182/blood.V94.2.818

Published: 1999

Journal Articles

Protein Replacement by Receptor-Mediated Endocytosis Corrects the Sensitivity of Fanconi Anemia Group C Cells to Mitomycin C

Hagop Youssoufian, Frank A.E. Kruyt, Xiaotong Li

Blood (1999) 93 (1): 363–369.

https://doi.org/10.1182/blood.V93.1.363

Published: 1999

Journal Articles

Abnormal Microsomal Detoxification Implicated in Fanconi Anemia Group C by Interaction of the FAC Protein With NADPH Cytochrome P450 Reductase

Frank A.E. Kruyt, Taizo Hoshino, Johnson M. Liu, Pius Joseph, Anil K. Jaiswal, Hagop Youssoufian

Blood (1998) 92 (9): 3050–3056.

https://doi.org/10.1182/blood.V92.9.3050

Published: 1998

Journal Articles

The Fanconi Anemia Proteins FAA and FAC Function in Different Cellular Compartments to Protect Against Cross-Linking Agent Cytotoxicity

Frank A.E. Kruyt, Hagop Youssoufian

Blood (1998) 92 (7): 2229–2236.

https://doi.org/10.1182/blood.V92.7.2229

Published: 1998

Journal Articles

Molecular Chaperone GRP94 Binds to the Fanconi Anemia Group C Protein and Regulates Its Intracellular Expression

Taizo Hoshino, Jianxiang Wang, Marcel P. Devetten, Nobuhisa Iwata, Sachiko Kajigaya, Robert J. Wise, Johnson M. Liu, Hagop Youssoufian

Blood (1998) 91 (11): 4379–4386.

https://doi.org/10.1182/blood.V91.11.4379

Published: 1998

Journal Articles

Cytoplasmic Localization of a Functionally Active Fanconi Anemia Group A–Green Fluorescent Protein Chimera in Human 293 Cells

Frank A.E. Kruyt, Quinten Waisfisz, Lonneke M. Dijkmans, Mario A.J.A. Hermsen, Hagop Youssoufian, Fré Arwert, Hans Joenje

Blood (1997) 90 (9): 3288–3295.

https://doi.org/10.1182/blood.V90.9.3288

Published: 1997

NARROW

Study of PC-002 (Sepantronium Bromide), a First-in-Class Inhibitor of Deubiquitinases (DUBs) Targeting Myc Degradation in Relapsed/Refractory c-Myc Rearranged High-Grade B Cell Lymphoma (HGBCL): Updated Phase 2 Results

Treatment of Relapsed/Refractory Hgbcl and Bukitt's Lymphoma with c-Myc Rearrangement: A Multi-Center, Open-Label, Phase 2 Study of PC-002 (SepB), a First-in-Class Deubiquitinase Inhibitor Inducing Myc Degradation

Duvelisib in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma from the Phase 2 Primo Trial: Dose Optimization Efficacy Update and Expansion Phase Initial Results

Dose Optimization of Duvelisib in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma from the Phase 2 Primo Trial: Selection of Regimen for the Dose-Expansion Phase

A Phase 2, Randomized, Open-Label, 2-Arm Study Comparing 2 Intermittent Dosing Schedules of Duvelisib in Patients with Indolent Non-Hodgkin Lymphoma (iNHL) (TEMPO)

Phase 1b Study of the Epichaperome Inhibitor PU-H71 Administered Orally with Ruxolitinib Continuation for the Treatment of Patients with Myelofibrosis

Phase 1 MMRC Trial of Selinexor, Carfilzomib (CFZ), and Dexamethasone (DEX) in Relapsed and Relapsed/Refractory Multiple Myeloma (RRMM)

Phase I Study of Selinexor, a Selective Inhibitor of Nuclear Export, in Combination with Fludarabine and Cytarabine in Pediatric Patients with Relapsed or Refractory AML

Correction of cross-linker sensitivity of Fanconi anemia group F cells by CD33-mediated protein transfer

Targeting of a Heterologous Protein to a Regulated Secretion Pathway in Cultured Endothelial Cells

Expression of the Fanconi Anemia Group A Gene ( Fanca ) During Mouse Embryogenesis

Protein Replacement by Receptor-Mediated Endocytosis Corrects the Sensitivity of Fanconi Anemia Group C Cells to Mitomycin C

Abnormal Microsomal Detoxification Implicated in Fanconi Anemia Group C by Interaction of the FAC Protein With NADPH Cytochrome P450 Reductase

The Fanconi Anemia Proteins FAA and FAC Function in Different Cellular Compartments to Protect Against Cross-Linking Agent Cytotoxicity

Molecular Chaperone GRP94 Binds to the Fanconi Anemia Group C Protein and Regulates Its Intracellular Expression

Cytoplasmic Localization of a Functionally Active Fanconi Anemia Group A–Green Fluorescent Protein Chimera in Human 293 Cells

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only